Sarepta Therapeutics Inc. (SRPT)
NASDAQ: SRPT
· Real-Time Price · USD
63.49
0.71 (1.13%)
At close: May 02, 2025, 3:59 PM
63.50
0.02%
After-hours: May 02, 2025, 05:52 PM EDT
1.13% (1D)
| Bid | 62.87 |
| Market Cap | 6.24B |
| Revenue (ttm) | 1.9B |
| Net Income (ttm) | 235.24M |
| EPS (ttm) | 2.34 |
| PE Ratio (ttm) | 27.13 |
| Forward PE | 4.76 |
| Analyst | Buy |
| Ask | 64.72 |
| Volume | 1,026,458 |
| Avg. Volume (20D) | 1,974,219 |
| Open | 63.50 |
| Previous Close | 62.78 |
| Day's Range | 63.09 - 64.16 |
| 52-Week Range | 48.01 - 173.25 |
| Beta | 0.92 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of ...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 4, 1997
Employees 1,372
Stock Exchange NASDAQ
Ticker Symbol SRPT
Website https://www.sarepta.com
Analyst Forecast
According to 22 analyst ratings, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is $167.5, which is an increase of 163.82% from the latest price.
Stock ForecastsNext Earnings Release
Sarepta Therapeutics Inc. is scheduled to release its earnings on May 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-6.18%
Sarepta Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
1 month ago
-9.36%
Sarepta Therapeutics shares are trading lower after RBC Capital downgraded the stock from Outperform to Sector Perform and lowered the price target from $161 to $87.
